Tobin Schilke serves as Chief Financial Officer at Crinetics Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing novel therapeutics for endocrine diseases. In this role, he leads all financial functions, including strategic planning, budgeting, investor relations, and capital markets activities, ensuring the company's financial stability amid advancing its pipeline toward commercialization. With more than 20 years of experience in biotechnology and pharmaceuticals, Schilke previously served as CFO at Sangamo Therapeutics from 2019 to 2021, where he oversaw financial operations during key clinical milestones and partnership deals. Earlier, he was Vice President of Finance and Treasurer at Achaogen Inc., managing treasury, accounting, and fundraising efforts, and held progressive finance leadership positions at Genentech, a member of the Roche Group, contributing to financial strategies for innovative drug development programs. Schilke's notable achievements include orchestrating multiple equity offerings, debt financings, and IPO preparations that have raised hundreds of millions to fuel biotech innovation. At Crinetics, his expertise has been pivotal in securing substantial non-dilutive funding and optimizing capital structure to support late-stage trials for paltusotine and other endocrine disorder candidates, positioning the company for sustained growth and value creation.